华领医药将于11月12日发布Dorzagliatin单药治疗III期临床试验24周顶线数据（HMM0301）
上海, Nov. 08, 2019 (GLOBE NEWSWIRE) — 华领医药（香港主板股票代码：2552）是一家专注于研发治疗全球2型糖尿病原创口服新药的生物技术公司，总部位于上海。今天华领医药宣布，dorzagliatin单药治疗临床试验(HMM0301)的24周顶线数据将于2019年11月12日公布，管理层将通过电话会议陈述该试验结果并回答各种问题。
Before you continue, please confirm the following:
Professional advisers only
I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.
Important Notice for Investors:
The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.
No Investment Advice:
The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.
High Risks:
Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.
Sole Responsibility:
The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.
No Guarantees:
Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.
Regional Restrictions:
The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.
Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.